| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 |
| Sales | 32,220 | 64,890 | 36,130 | 42,880 | 82,500 |
| Sales Growth | -50.35% | +79.60% | -15.74% | -48.02% | +590.95% |
| Net Income | -131,760 | -55,360 | -55,490 | -37,970 | 0 |
| Net Income Growth | -138.01% | +0.23% | -46.14% | unch | +100.00% |
Chemocentryx Inc (CCXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
ChemoCentryx, Inc., being a clinical-stage biopharmaceutical company, focuses on discovering, developing and commercializing orally-administered medications targeted at autoimmune diseases, inflammatory disorders & cancer. Its lead drug, avacopan, is recognized as an adjunctive treatment combined with standard therapy for two main forms of granulomatosis with polyangiitis (GPA) & microscopic polyangiitis (MPA). The drug is marketed under the brand name Tavneos. Avacopan enjoys orphan drug designation in the U.S. and in Europe for treating GPA & MPA.'The company is also developing avacopan in other indications like complement 3 glomerulopathy and hidradenitis suppurativa, and plans to initiate a clinical study to evaluate the candidate in lupus nephritis patients.'Besides avacopan, it is developing CCX559, its orally-administered inhibitor for the treatment of various cancers. ChemoCentryx partnered with Vifor Pharma, providing the latter with exclusive rights to commercialise Tavneos outside the U.S.
Fiscal Year End Date: 12/31